Breaking Finance News

A report released today by Zacks Investment Research about Arbutus Biopharma Corp (NASDAQ:ABUS) bumps the target price to $4.00

Indicating a possible upside of 0.09%, Zacks Investment Research increased the target price of Arbutus Biopharma Corp (NASDAQ:ABUS) to $4.00

Displaying a price of $3.66, Arbutus Biopharma Corp (NASDAQ:ABUS) traded 3.71% higher on the day. The last closing price is down -13.80% from the two hundred day moving average, compared to the S&P 500 which has decreased -0.01% over the same period. ABUS has recorded a 50-day moving average of $3.76 and a 200-day average of $4.06. Trade Volume was up over the average, with 222,315 shares of ABUS changing hands over the typical 125,046

See Chart Below

Arbutus Biopharma Corp (NASDAQ:ABUS)

Arbutus Biopharma Corp has a 52 week low of $2.72 and a 52 week high of $6.74 Arbutus Biopharma Corp’s market capitalization is presently $0.

A total of 5 analysts have released a report on Arbutus Biopharma Corp. Two analysts rating the company a strong buy, three analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally 0 brokerages rating the stock a sell with a average stock price target of $13.80.

Brief Synopsis On Arbutus Biopharma Corp (NASDAQ:ABUS)

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company's lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.